Predictors of Hospitalization, Using Multivariate Logistic Regression and Controlling for Treatment Regimen Received.

<p>CI = confidence interval; HMO = health maintenance organization; POS = point of service; PPO = preferred provider organization.</p

Sample Selection Flow Chart.

<p>Sample Selection Flow Chart.</p

Predictors of Hospitalization, Using Multivariate Logistic Regression and Controlling for Adherence Threshold.

<p>CI = confidence interval; HMO = health maintenance organization; POS = point of service; PPO = preferred provider organization.</p

Characteristics of the Study Sample, by Cohort.

<p>ART = antiretroviral therapy; HMO = health maintenance organization; POS = point of service; PPO = preferred provider organization; SD = standard deviation.</p>a<p>Evaluated in the 6-month pre-index period.</p

Adjusted Rate of Hospitalization, by Cohort.

<p>Adjusted Rate of Hospitalization, by Cohort.</p

Frequency of Hospitalizations, by Cohort^a.

<p>Frequency of Hospitalizations, by Cohort^a.</p

Adherence to ART Regimens, by Cohort.

<p>ART = antiretroviral therapy; MPR = medication possession ratio; SD = standard deviation.</p>a<p><i>P</i> values calculated from Students t-test for mean MPR, Wilcoxon rank sum tests for median MPR, and chi-square for distribution by MPR threshold.</p

Average estimated glomerular filtration rate in patients during and after telaprevir therapy, by baseline kidney function.

<p>3a. Baseline eGFR ≥ 90 mL/min/1.73m² 3b. Baseline eGFR < 90 mL/min/1.73m². Mean eGFR (solid gray circle) and one-standard deviation error bars are shown with shading at baseline, on treatment (nadir), 12 weeks after finishing telaprevir, while still on PegIFN and RBV, and then one year after completing telaprevir, off all treatment. P < 0.01 for changes between baseline eGFR and eGFR while on telaprevir in both groups. There is no signficant difference between baseline eGFR and eGFR 12 weeks or one year post telaprevir. Fig 3a shows patients with baseline eGFR ≥ 90mL/min/1.73m². (N = 44). 3b.) Includes patients with baseline eGFR < 90mL/min/1.73m² (N = 34). Values that fell outside of one standard deviation are shown with hollow gray circles. eGFR = estimated glomerular filtration rate.</p

Univariate and multivariable logistic regression model predicting development of significant creatinine rise during therapy with telaprevir.

<p>^{Abbreviations: HIV = human immunodeficiency virus, eGFR = estimated glomerular filtration rate}</p><p>Univariate and multivariable logistic regression model predicting development of significant creatinine rise during therapy with telaprevir.</p

Peak rise in serum creatinine during telaprevir therapy.

<p>Bar graphs represent the numbers of patients who experienced a maximum rise in serum creatinine in the above ranges. The majority (55%) of patients experienced a small (< 0.2mg/dl) rise in creatinine during telaprevir therapy. However, thirty-one percent developed significant creatinine rise ≥ 0.3mg/dl, shown by a dashed vertical line.</p